Advertisement
ALC vs SYK
Which Stock Would AI Choose? Alcon (ALC) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- Alcon (ALC) is a global eye-care leader spanning surgical equipment, intraocular lenses, contact lenses, and ocular health, while Stryker (SYK) is a diversified medical-technology company across orthopaedics, MedSurg, and neurotechnology.
- Both companies delivered second-quarter 2026 earnings beats, yet their stock reactions diverged: ALC climbed on raised guidance, while SYK fell as management tightened its outlook.
- SYK showed stronger recent momentum with roughly 9% organic sales growth, but it is still working through a first-quarter cybersecurity disruption and a leadership succession.
- ALC is more exposed to tariff costs, a soft cataract market, and competitive pressure in intraocular lenses, offset by a rich new-product pipeline.
- Scale and sector focus differ sharply: SYK carries a market capitalization near $112 billion, roughly three times Alcon's roughly $32–34 billion.
- For more detail, explore ALC Major News and ALC Today's Price Move, along with SYK Major News and SYK Today's Price Move.
- To see how automated strategies are positioning across names like these, explore Trending AI Robots.
Introduction
Alcon and Stryker are both large-cap healthcare names, but they occupy different corners of the medical-device landscape. Alcon is the world's largest dedicated eye-care company, while Stryker is a broad orthopaedics and surgical-technology franchise. Investors comparing the two are typically weighing a focused, innovation-driven specialist against a diversified, acquisition-heavy growth platform. Both stocks offer exposure to aging demographics and rising procedure volumes, yet their risk profiles, growth drivers, and recent stock behavior have diverged. This comparison examines their recent performance, business models, and relative market positioning to help traders and long-term investors evaluate which profile better fits current market conditions.
ALC Overview and Recent Performance
Alcon is a Swiss-headquartered eye-care company whose portfolio spans two segments: Surgical (implantables, consumables, and equipment) and Vision Care (contact lenses and ocular health). In its most recent quarterly report, Alcon posted sales of roughly $2.78 billion, up about 8% year over year, with core earnings per share (EPS) rising 10.5% and beating consensus estimates. The company also lifted its full-year core EPS growth guidance to a 12%–15% range, which helped support the stock in subsequent trading.
Sentiment has been shaped by a robust launch cadence, including the Unity surgical platform, PanOptix Pro intraocular lenses, the Tryptyr dry-eye treatment, and the Valeda device for age-related macular degeneration. However, these positives are balanced by headwinds: tariff-related cost pressure, a persistently soft cataract procedure market, and intense competitive pressure in intraocular lenses, particularly outside the United States. Over the past year, ALC has underperformed the broader market, reflecting these mixed dynamics.
SYK Overview and Recent Performance
Stryker is a Michigan-based medical-technology company operating across MedSurg and Neurotechnology, plus Orthopaedics. In its latest quarter, Stryker reported revenue of about $6.59 billion, up 9.4% year over year, with adjusted EPS of $3.69, a 17.9% increase that beat estimates. Organic sales advanced roughly 9%, driven by record Mako robotic-system installations and broad demand across its portfolio.
That strong recovery followed a first quarter disrupted by a global cybersecurity incident that temporarily halted production and delayed shipments. Although operations were fully restored by early April, remediation costs and lingering vascular supply constraints remain watchpoints. Stryker also announced a planned leadership transition, with a 27-year insider set to become CEO in 2027 while the current chief executive moves to Executive Chair. Despite the earnings beat, SYK shares fell after management tightened full-year guidance rather than raising it, underscoring lingering execution concerns.
Trending AI Robots
For traders seeking a systematic view of how names like Alcon and Stryker are positioned, Tickeron's Trending AI Robots page offers a curated view of the platform's automated trading strategies. Tickeron hosts hundreds of AI trading bots that collectively trade thousands of different tickers, but only the strategies best suited to prevailing market conditions earn a place in the Trending section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the specific tickers they trade, giving investors a range of approaches to review. The page is designed to help users quickly identify which automated strategies are currently resonating with market conditions, rather than sifting through the full catalog manually. To explore the current leaders, visit Trending AI Robots.
Head-to-Head Comparison
The two companies differ most fundamentally in breadth and scale. Stryker's roughly $112 billion market capitalization reflects a diversified platform spanning joint replacement, surgical instruments, hospital beds, and neurotechnology, while Alcon's roughly $32–34 billion valuation reflects a concentrated bet on eye care. That concentration gives Alcon a clearer innovation narrative but also heightens sensitivity to a single category's procedure volumes and competitive shifts.
On momentum, Stryker's near-9% organic growth and margin expansion currently outpace Alcon's mid-to-high-single-digit top-line trajectory. Yet Stryker carries its own operational overhang from the cybersecurity incident and a CEO transition, while Alcon contends with tariffs and China weakness. From a sentiment standpoint, Alcon benefits from raised guidance and a strong product pipeline, whereas Stryker's guidance tightening tempered an otherwise strong quarter. Risk-tolerant investors may favor Alcon's innovation-driven optionality; those seeking diversification and scale may find Stryker's broader franchise more resilient.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative momentum, and catalyst clarity, Tickeron's AI would likely lean toward Stryker at present. Stryker's stronger organic growth, expanding margins, record robotic-system installations, and diversified revenue base suggest more stable and consistent near-term positioning, despite the lingering operational overhang from its cyber incident. Alcon's raised guidance and product pipeline are meaningful positives, but its softer relative performance, tariff exposure, and competitive intraocular-lens pressures introduce more uncertainty. This assessment is probabilistic rather than definitive, reflecting current data rather than a forecast of future returns.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALC is a Buy and SYK is a Buy.
Momentum Indicator for ALC turns positive, indicating new upward trend
ALC saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned positive. In 61 of the 91 cases, the stock moved higher in the following days. The odds of a move higher are at 67%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ALC just turned positive on October 09, 2026. Looking at past instances where ALC's MACD turned positive, the stock continued to rise in 32 of 53 cases over the following month. The odds of a continued upward trend are 60%.
ALC moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ALC crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 60%.
Following a +3.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALC advanced for three days, in 175 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
The Aroon Indicator entered an Uptrend today. In 95 of 218 cases where ALC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 44%.
Bearish Trend Analysis
The 10-day RSI Indicator for ALC moved out of overbought territory on November 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 17 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 35 of 67 cases where ALC's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
ALC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ALC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.678) is normal, around the industry mean (4.964). P/E Ratio (56.773) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (1.165) is also within normal values, averaging (4.143). Dividend Yield (0.014) settles around the average of (0.005) among similar stocks. P/S Ratio (2.996) is also within normal values, averaging (56.876).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for SYK turns positive, indicating new upward trend
SYK saw its Momentum Indicator move above the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 52 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 58%.
Technical Analysis (Indicators)
Bullish Trend Analysis
SYK moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SYK crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 55%.
Following a +10.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYK advanced for three days, in 174 of 305 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
The Aroon Indicator entered an Uptrend today. In 128 of 258 cases where SYK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 50%.
Bearish Trend Analysis
The 10-day RSI Indicator for SYK moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 25 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 66%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 59 cases where SYK's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 56%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 50%.
SYK broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. SYK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 60 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.211) is normal, around the industry mean (4.142). P/E Ratio (33.491) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (1.289) is also within normal values, averaging (11.253). Dividend Yield (0.011) settles around the average of (0.011) among similar stocks. P/S Ratio (4.259) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
ALC | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 17 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 74 Overvalued | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 60 | |
SMR RATING 1..100 | 88 | 52 | |
PRICE GROWTH RATING 1..100 | 43 | 46 | |
P/E GROWTH RATING 1..100 | 8 | 79 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALC's Valuation (74) in the Hospital Or Nursing Management industry is in the same range as SYK (79) in the Medical Specialties industry. This means that ALC’s stock grew similarly to SYK’s over the last 12 months.
SYK's Profit vs Risk Rating (60) in the Medical Specialties industry is somewhat better than the same rating for ALC (100) in the Hospital Or Nursing Management industry. This means that SYK’s stock grew somewhat faster than ALC’s over the last 12 months.
SYK's SMR Rating (52) in the Medical Specialties industry is somewhat better than the same rating for ALC (88) in the Hospital Or Nursing Management industry. This means that SYK’s stock grew somewhat faster than ALC’s over the last 12 months.
ALC's Price Growth Rating (43) in the Hospital Or Nursing Management industry is in the same range as SYK (46) in the Medical Specialties industry. This means that ALC’s stock grew similarly to SYK’s over the last 12 months.
ALC's P/E Growth Rating (8) in the Hospital Or Nursing Management industry is significantly better than the same rating for SYK (79) in the Medical Specialties industry. This means that ALC’s stock grew significantly faster than SYK’s over the last 12 months.
| ALC | SYK | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 61% | 2 days ago 66% |
| Stochastic ODDS (%) | 2 days ago 52% | 2 days ago 56% |
| Momentum ODDS (%) | 2 days ago 67% | 2 days ago 58% |
| MACD ODDS (%) | 2 days ago 60% | N/A |
| TrendWeek ODDS (%) | 2 days ago 59% | 2 days ago 57% |
| TrendMonth ODDS (%) | 2 days ago 57% | 2 days ago 50% |
| Advances ODDS (%) | 10 days ago 56% | 8 days ago 57% |
| Declines ODDS (%) | 6 days ago 55% | 2 days ago 50% |
| BollingerBands ODDS (%) | 2 days ago 55% | 2 days ago 63% |
| Aroon ODDS (%) | 2 days ago 44% | 2 days ago 50% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALC’s FA Score shows that 1 FA rating(s) are green while SYK’s FA Score has 0 green FA rating(s).
- ALC’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALC’s TA Score shows that 6 TA indicator(s) are bullish while SYK’s TA Score has 5 bullish TA indicator(s).
- ALC’s TA Score: 6 bullish, 4 bearish.
- SYK’s TA Score: 5 bullish, 4 bearish.
Price Growth
ALC (@Pharmaceuticals: Other) experienced а +2.34% price change this week, while SYK (@Medical/Nursing Services) price change was +4.42% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +1.96%. For the same industry, the average monthly price growth was +6.35%, and the average quarterly price growth was +22.73%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -2.89%. For the same industry, the average monthly price growth was -4.69%, and the average quarterly price growth was -1.76%.
Reported Earning Dates
ALC is expected to report earnings on Mar 02, 2027.
SYK is expected to report earnings on Feb 02, 2027.
Industries' Descriptions
@Pharmaceuticals: Other (+1.96% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-2.89% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
Advertisement
ALC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALC has been loosely correlated with SYK. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ALC jumps, then SYK could also see price increases.
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.